Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 7, 2021

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. Licensed wholesalers will be able to import larger quantities of cannabis-based products, and hold supplies for future use by patients with prescriptions, according to a government release.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. topiramate. rufinamide. zonisamide. eslicarbazepine.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. topiramate. rufinamide. zonisamide.

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

JUNE 1, 2021

As we prepare for a potential world-class launch of Vicineum, I strongly believe that these leaders will not only bring diverse and invaluable expertise to our team but will also drive the Company to continue executing our mission to save and improve the lives of patients with cancer.”. CAMBRIDGE, Mass.–(BUSINESS About Sesen Bio.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Third-party clinical studies investigating oral psilocybin have reported compelling anti-depressant effects. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

SEPTEMBER 20, 2021

Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. US Food & Drug Administration website.

CBD 144

CBD Seed-To-Sale Food Access 144

Canna Law Blog

OCTOBER 5, 2022

Last year, it recommended that the government allow the use of marijuana to treat “refractory epilepsy.” ” However, that didn’t go anywhere aside from Japan quietly clearing Epidiolex for clinical trials for Dravet and Lennox-Gastaut syndromes back in 2019.

Marijuana 93

Marijuana Seed-To-Sale Clinical Trials Epilepsy 93

Cannabis Law Report

JANUARY 26, 2022

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. Our promising Phase 3 results lead us to apply for the Innovation Passport. Berra Yazar-Klosinski, Ph.D. Corine de Boer, M.D.,

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. 19 vaccine candidate in Mexico.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. Robert Schatz. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

DECEMBER 28, 2021

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax anticipates enrollment of the first patient by early second quarter of 2022. to conduct this study in Canada. For more information, please visit www.virpaxpharma.com.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

The Cannigma

MAY 7, 2021

There were somewhat of a, I want to say grey, but it wasn’t the pharma routes for patients in the US who wanted to get certain products, you know? What do those more pharmaceutical standards mean for patients? You know, you can’t isolate it in the same manner in order to reproduce and manufacture a certain product.

Supply Chain 120

Supply Chain Patients Access Hemp 120

Cannabis Law Report

NOVEMBER 15, 2021

Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. VRP324 represents our first CNS disorder product indication. On September 9, 2021, Jeffrey A. Forward-Looking Statement.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

“We are encouraged with the progress that has been made under the CRADA with NCATS and the NIH Helping to End Addiction Long-term (HEAL) initiative, as we believe that it may help Virpax develop an effective and safe alternative to conventional opioids used by patients to manage acute and chronic pain. Forward-Looking Statement. Chipman, CPA.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

JULY 15, 2022

“It’s very important from our perspective to ensure that the Australian patient gets medicine first. The first medicinal cannabis ‘mother’ plants are expected to be imported from Israel within a month, with manufacturing scheduled to begin within the first half of this year, to supply 5,000 Australian patients.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.

Research and Development 52

Research and Development Medicine Access Media 52

SMPL

MAY 26, 2020

We were talking about, ‘What can we do with this?’ ” recalled Samantha Miller, who hosted the event at her split-level house, wedged between redwoods and a creek below. A headstrong biochemist, she had been growing marijuana since the age of 14 and had just quit a six-figure job to start her own cannabis testing lab.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Green Relief

MAY 13, 2018

A 2014 study found that traumatic brain injury ( TBI ) patients who tested positive for THC were more likely to survive with less impairment than TBI patients who abstained from marijuana. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

THC 64

THC CBD Cannabinoids Research and Development 64

Green Relief

MAY 12, 2018

A 2014 study found that traumatic brain injury ( TBI ) patients who tested positive for THC were more likely to survive with less impairment than TBI patients who abstained from marijuana. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

The Cannigma

DECEMBER 22, 2021

It doesn’t mean, necessarily, that the market should go to full legalization within a year or two, because it won’t happen so fast, but you can have more patients with other medical indications that were not given cannabis before. Obviously, that means that there are more patients and there are more products to sell.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. This is true even if the CBD comes from industrial hemp.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

DECEMBER 30, 2019

Since 2014, annual appropriations bills have been amended to include a spending restriction to prevent the Department of Justice from enforcing the federal prohibition of marijuana against state-legal medical cannabis programs, businesses, and patients. Included in the final FY 2020 spending package). It took immediate effect upon passage.

Legislation 59

Legislation Patients Access Banking 59